About Elongation factor Ts, mitochondrial
Elongation factor Ts, mitochondrial (TSFM) is a protein
from Homo sapiens identified by UniProt accession
P43897, 325 residues long.
MolForge cross-references it against 0 known binders and
84 disease associations.
Target properties
| Protein name | Elongation factor Ts, mitochondrial |
| UniProt accession | P43897 |
| Gene | TSFM |
| Organism | Homo sapiens |
| Length | 325 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (84)
Diseases linked to this target (Open Targets).
- Fatal mitochondrial disease due to combined oxidative phosphorylation deficiency 3 · score 0.78
- fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 · score 0.73
- steroid-resistant nephrotic syndrome · score 0.45
- nephrotic syndrome · score 0.44
- genetic disorder · score 0.41
- mitochondrial disease · score 0.37
- neurodegenerative disease · score 0.37
- dilated cardiomyopathy · score 0.33
- Leigh syndrome · score 0.19
- Seizure · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P43897-F1 | alphafold | PREDICTED | 87.94 | — |
Amino-acid sequence (325 residues)
MSLLRSLRVF LVARTGSYPA GSLLRQSPQP RHTFYAGPRL SASASSKELL MKLRRKTGYS FVNCKKALET CGGDLKQAEI WLHKEAQKEG WSKAAKLQGR KTKEGLIGLL QEGNTTVLVE VNCETDFVSR NLKFQLLVQQ VALGTMMHCQ TLKDQPSAYS KGFLNSSELS GLPAGPDREG SLKDQLALAI GKLGENMILK RAAWVKVPSG FYVGSYVHGA MQSPSLHKLV LGKYGALVIC ETSEQKTNLE DVGRRLGQHV VGMAPLSVGS LDDEPGGEAE TKMLSQPYLL DPSITLGQYV QPQGVSVVDF VRFECGEGEE AAETE
Explore Elongation factor Ts, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets